Literature DB >> 3298415

Effects of captopril on renal function in patients with cirrhosis and ascites.

G Daskalopoulos, M Pinzani, N Murray, R Hirschberg, R D Zipser.   

Abstract

Blockade of angiotensin-converting enzyme has been variously reported to increase or to decrease sodium excretion in patients with cirrhosis and ascites. We administered captopril (50-150 mg) to 11 patients with cirrhosis and ascites to determine the effects on blood pressure, renal blood flow and sodium excretion. Plasma renin activity increased and mean blood pressure fell (by 14 mm Hg). Para-aminohippurate clearances increased from 321 +/- 53 to 559 +/- 83 ml/min (P less than 0.005), but inulin clearances were minimally altered (73 +/- 8 to 76 +/- 7 ml/min), suggesting preferential dilation of glomerular efferent arterioles. Despite unchanged glomerular delivery of sodium, urinary sodium excretion fell in all subjects (from 2.70 +/- 1.00 to 0.48 +/- 0.21 mEq/h), urinary volume was reduced (377 +/- 55 to 182 +/- 42 ml/h, P less than 0.005), and the natriuretic effect of furosemide was blunted. The antinatriuretic effect of captopril may be mediated by reduced angiotensin II-mediated sodium excretion, by decreased prostaglandin production, and/or by indirect effects of reduced blood pressure. Captopril impairs rather than promotes sodium excretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298415     DOI: 10.1016/s0168-8278(87)80542-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  9 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 2.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

3.  [Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites].

Authors:  R Brunkhorst; E Wrenger; K Kühn; F W Schmidt; K Koch
Journal:  Klin Wochenschr       Date:  1989-08-01

Review 4.  Management of hepatorenal syndrome in patients with cirrhosis.

Authors:  Vicente Arroyo; Javier Fernández
Journal:  Nat Rev Nephrol       Date:  2011-08-09       Impact factor: 28.314

Review 5.  New clues to the pathophysiology of hepatorenal failure.

Authors:  F Lang; W Gerok; D Häussinger
Journal:  Clin Investig       Date:  1993-02

6.  Liver abnormalities in cardiac diseases and heart failure.

Authors:  Alicia M Alvarez; Debabrata Mukherjee
Journal:  Int J Angiol       Date:  2011-09

Review 7.  From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?

Authors:  Anna Sessa; Manon Allaire; Pascal Lebray; Mourad Medmoun; Alberto Tiritilli; Pierre Iaria; Jean-François Cadranel
Journal:  JHEP Rep       Date:  2021-01-27

Review 8.  Drug administration in chronic liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.228

Review 9.  Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Authors:  John S Lubel; Chandana B Herath; Louise M Burrell; Peter W Angus
Journal:  J Gastroenterol Hepatol       Date:  2008-06-28       Impact factor: 4.029

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.